Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishesa minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.		N/A

Cell materials	Yes (indicate where provided:section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		N/A
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		N/A

Experimental animals	Yes (indicate where provided:section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		N/A
Animal observed in or captured from the field: Provide species, sex and age where possible		N/A
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID		N/A

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants:provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		N/A
Microbes:provide species and strain, unique accession number if available, and source		N/A

Human research participants	Yes (indicate where provided:section/paragraph)	n/a
Identify authority granting ethics approval(IRB or equivalent committee(s), provide reference number for approval.	Section: Materials and methods; paragraph: Study subjects The blood samples of all the participants were stored in the Bio-Bank of resources “Tuberculosis Researches” in the Department of Laboratory Medicine, West China Hospital, Sichuan University, China	
Provide statement confirming informed consent obtained from study participants.	Section: Materials and methods; paragraph: Study subjects Ethical approval for this study was obtained from the Institutional Review Board of the West China Hospital of Sichuan University.	
Report on age and sex for all study participants.	Section:Results; paragraph: Demographic characteristics of the subjects In total, 746 tuberculosis patients were consecutively included, 118 in ATDH group and 628 in Non-ATDH group. The prevalence rate of ATDH was 15.82 % (118/746). The age of the ATDH group and Non-ATDH group were 42.85±18.44 and 40.92±15.72 (p=0.284). There were 69 (58.47%) males in ATDH group and 375(59.71%) male in Non-ATDH group (p=0.801).	

Design

Studyprotocol	Yes (indicate where provided:section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR**cite DOI in manuscript.		N/A

Laboratoryprotocol	Yes (indicate where provided:section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.		N/A

Experimental study design (statistics details)	Yes (indicate where provided:section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.	Section:Materials and methods; paragraph: Study subjects	
Sample size determination	A total of 746 confirmed tuberculosis patients were recruited at West China Hospital between December 2014 and April 2018.	
Randomisation	This study Included all subjects that meet the criteria during the observation period.	
Blinding	This is a retrospective observational experiment.	
Inclusion/exclusion criteria	The inclusion criteria for ATDH group were as follows: (a) normal serum alanine aminotransferase (ALT) (0-40 IU/L) and aspartate aminotransferase (AST) (0-40 IU/L) before treatment; (b) ALT and/or AST levels⩾3×upper limit of normal (ULN) (120 IU/L) with hepatitis symptoms; (c) ALT and/or AST levels⩾5×ULN (200 IU/L) with or without symptoms; (d) total bilirubin (TBIL) ⩾1.5×ULN (42 μmol/L); (e) no administration of other potential hepatotoxic drugs; (f) no history of infection with hepatitis virus or human immunodeficiency virus.The inclusion criteria for the non-ATDH group were normal serum ALT, AST and TBIL values before and after treatment.	

Sample definition and in-laboratory replication	Yes (indicate where provided:section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Section:Materials and methods; paragraph: Candidate single nucleotide polymorphism selection and Genotyping To ensure the repeatability and stability of the genotyping, 30 samples were randomly selected for double-blind experiments, and all the genotype calling success rates were greater than 99.0%.	
Define whether data describe technical or biological replicates	Section:Materials and methods; paragraph: Candidate single nucleotide polymorphism selection and Genotyping	

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Section:Materials and methods; paragraph: Study subjects Ethical approval for this study was obtained from the Institutional Review Board of the West China Hospital	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		N/A

Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Section: Materials and methods; paragraph: Study subjects The blood samples of all the participants were stored in the Bio-Bank of resources “Tuberculosis Researches” in	

Dual Use Research of Concern (DURC)	**Yes (indicate where provided:section/paragraph)**	**n/a**
If study is subject to dual use research ofconcern, statethe authority granting approval and reference number for the regulatory approval		N/A

Analysis

Attrition	Yes (indicate where provided:section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	criteria for inclusion were determined and specified in advance.	

Statistics	Yes (indicate where provided:section/paragraph)	n/a
Describestatistical tests used and justify choice of tests.	Section:Materials and methods; paragraph: Statistical analysisThe demographic data of the subjects in the ATDH group and Non-ATDH group were compared using the chi-square test (categorical variable), independent t-test or Wilcoxon rank sum test (continuous variables) by SPSS (version 17.0). Associations between SNPs and the risk of ATDH were evaluated by Plink (version 1.07). The linkage disequilibrium (LD) and haplotype analysis were conducted by Haplotype (version 4.2). The SNP-SNP interactions associated with susceptibility to ATDH was analyzed by Multifactor Dimensionality Reduction Software (MDR) (version 3.0.1). Schematic diagram was conducted by Cytoscape (version3.7.1). The odds ratio (OR) with 95% confidence interval (95%CI) was used as a measure of associations and two-sided values of $p < 0.05$ were considered statistically significant.	

Data Availability	Yes (indicate where provided:section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	The data used to support the findings of this study are included with in the article and the supplementary information file. All data, models, or code generated or used during the study are available in a repository or online in accordance with funder data retention policies.	
If data are publicly available, provide accession number in repository or DOI or URL.		N/A
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		N/A

Code Availability	Yes (indicate where provided:section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		N/A
If code is publicly available, provide accession number in repository, or DOI or URL.		N/A

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: https://dx.doi.org/10.21037/apm-21-2924